[Involvement of dynamic HBeAg quantitation and response during chronic hepatitis B treatment].
To observe the changes in quantity of serum HBeAg and the Correlation with response during chronic hepatitis B treatment using interferon-alpha or nucleotside analogue, evaluate the predictive value of dynamic HBeAg quantitation to antiviral response. 53 cases treated with interferon-alpha and 70 cases treated with nucleotide analogue for 48 weeks. Used the Electro chemiluminescence immunoassay (ECLIA) to measure the quantity of the serum HBeAg before treatment and 12 weeks, 24 weeks and 48 weeks after treatment, analysis the correlation of dynamic HBeAg quantitation with antiviral response. After 48 weeks treatment, whether interferon-alpha group or nucleotide analogue group, the complete responser quantity of HBeAg before treatment was no significant correlation compared with non-complete responser (P > 0.05), but at treatment weeks 12 and 24 had correlation with the serum HBeAg level and HBeAg decline degree (P < 0.05), deferent HBeAg titer and HBeAg quantatition decline degree during treatment achieved deferent complete response rate, HBeAg titer lesser than 100 U/ml and HBeAg quantatition decline degree higher than 90% at treatment weeks 24 achieved more complete response rate After 48 weeks treatment. During the treatment CHB with interferon-alpha or nucleotside analogue, the dynamic changes in quantity of serum HBeAg has a relationship with response.